Paladin Advisory Group’s Johnson & Johnson JNJ Stock Holding History

Paladin Advisory Group’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-245	Closed	-$43.3K	–	387
2022 Q4	$43.3K	Hold	245	–	–	0.04%	162
2022 Q3	$40K	Hold	245	–	–	0.04%	168
2022 Q2	$43K	Buy	+245	New	+$43.7K	0.04%	171
2022 Q1	–	Sell	-245	Closed	-$41K	–	402
2021 Q4	$41K	Buy	+245	New	+$40.1K	0.03%	186

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Paladin Advisory Group's JNJ Position: Q4 2023 in Review

Paladin Advisory Group sold out of Johnson & Johnson (JNJ) in Q4 2023, closing a stake of 150 shares — an estimated $23.4K sold.

Paladin Advisory Group first reported a position in JNJ in Q1 2022 and held it in 4 quarters. The position peaked at $43K in Q1 2022. 3,868 funds tracked by Wall St. Rank hold JNJ as of Q4 2023.

Paladin Advisory Group reported no remaining Johnson & Johnson position as of Q4 2023 after selling out during the quarter.
Paladin Advisory Group sold 150 Johnson & Johnson shares in Q4 2023, an estimated $23.4K.
Paladin Advisory Group first reported a position in Johnson & Johnson in Q1 2022 and held it in 4 quarters.
Paladin Advisory Group's Johnson & Johnson position peaked at $43K in Q1 2022.
3,868 funds tracked by Wall St. Rank held Johnson & Johnson as of Q4 2023.

Based on Paladin Advisory Group's 13F filing for Q4 2023, filed 31 Jan 2024.